Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

US WorldMeds And Salix Launch Lucemyra In The U.S.

By US WorldMeds, LLC. and Salix Pharmaceuticals | August 6, 2018

US WorldMeds, LLC. and Salix Pharmaceuticals, a wholly owned subsidiary of Bausch Health Companies Inc. announced the U.S. launch and availability of Lucemyra (lofexidine) 0.18 mg tablets, the first and only non-opioid medication indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults.

The Centers for Disease Control and Prevention estimates that more than 115 people in the U.S. die each day from opioid overdose.1 Often overlooked, opioid withdrawal is one of the most powerful barriers keeping people from discontinuing opioids. Many people have such difficulty tolerating symptoms of withdrawal that the desire to avoid them can perpetuate their opioid use.2 In a survey of people with chronic pain, 57 percent of patients reported avoidance of withdrawal as the primary reason for continued use of prescription opioids.3

“Many people who wish to stop taking opioids are searching for a treatment that will help get them through the agonizing symptoms of withdrawal,” said P. Breckinridge Jones, chief executive officer and founder, US WorldMeds. “The availability of Lucemyra broadens the range of evidence-based pharmacological options available to healthcare providers, so they can manage the challenges of withdrawal and facilitate their patients’ abrupt discontinuation of opioids.”

The FDA approved Lucemyra in May 2018. The product’s development involved a grant from and close collaboration with the National Institute on Drug Abuse, part of the National Institutes of Health. In June, US WorldMeds and Salix Pharmaceuticals entered into an exclusive co-promotion agreement for Lucemyra.

Today, Salix and US WorldMeds have initiated sales force efforts in the promotion of Lucemyra to primary care physicians, pain management specialists, and psychiatrists focused on addiction medicine and addictionologists.

“Lucemyra addresses a large and growing need in the field of primary care and pain management. Opioid withdrawal is frequently overlooked and can present a significant challenge in the discontinuation of opioid-based pain medications. By effectively intervening during withdrawal and helping to control severe, disabling withdrawal symptoms, Lucemyra can help provide a starting point toward recovery,” said Mark McKenna, president, Salix Pharmaceuticals. 

References 

  1. CDC/NCHS, National Vital Statistics System, Mortality. CDC Wonder, Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://wonder.cdc.gov.
  2. Kosten TR, George TP. The Neurobiology of Opioid Dependence: Implications for Treatment. Science & Practice Perspectives. 2002;1(1):13-20.
  3. Weiss RD. J Subst Abuse Treat. 2014 August; 47(2): 140–145. doi:10.1016/j.jsat.2014.03.004.

(Source: US WorldMeds, LLC.; Salix Pharmaceuticals​)

 


Filed Under: Drug Discovery

 

Related Articles Read More >

EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE